Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 16:3.
doi: 10.3402/jmahp.v3.28760. eCollection 2015.

A review of the value of innovation in inhalers for COPD and asthma

Johann Christian Virchow  1 , Cezmi A Akdis  2 , Josep Darba  3 , Richard Dekhuijzen  4 , Sylvia Hartl  5 , Gisela Kobelt  6 , Albert Roger  7 , Steven Simoens  8 , Mondher Toumi  9 , Ben Woodhouse  10 , Adam Plich  11 , Saku Torvinen  11
Affiliations

A review of the value of innovation in inhalers for COPD and asthma

Johann Christian Virchow et al. J Mark Access Health Policy. .

Abstract

Background: Appropriate use of inhaled therapies for asthma and chronic obstructive pulmonary disease (COPD) is critical to ensuring good patient outcomes, efficient use of healthcare resources and limiting the effects of high-morbidity. The appropriate choice of inhaler and active therapy, incorporating patient preferences, can help improve treatment adherence and long-term outcomes. Despite this, many current inhalers are non-intuitive to use, and require extensive training.

Methods: In this review, an expert panel considers the evidence for the use of inhaler devices in management of COPD and asthma. The panel also evaluates the value of innovation in inhaler technologies, which optimise the use of existing molecules from a clinical, economic and societal perspective.

Conclusions: The panel conclusion is that there remains a substantial unmet need in inhaler technology and that innovation in inhaler devices can provide real-world health benefits to patients. Furthermore, we recommend that these innovations should be supported by healthcare systems through appropriate pricing and reimbursement mechanisms.

Keywords: Asthma; Chronic obstructive pulmonary disease; adherence; dry powder inhaler; innovation; medication errors; metered dose inhaler; patient compliance; patient preference; value.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Respiratory Society. European lung white book. 2013. Available from: http://www.erswhitebook.org/ [cited 30 July 2015].
    1. Global Initiative for Asthma (GINA) Pocket guide for asthma management and prevention (for adults and children older than 5 years) A pocket guide for physicians and nurses [updated 2015]. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Pocket_2015.pdf [cited 30 July 2015]
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2013] Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf [cited 30 July 2015]
    1. To KW, Lee WM, Choi KC, Yu D, Chau J, Lee I. Educational and supportive interventions for improving adherence to inhalation therapy in people with chronic respiratory diseases: A systematic review protocol. JBI Database Syst Rev Implement Rep. 2013;11:329–45.
    1. Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–31. - PubMed